What is the approach to treatment of myasthenia gravis (MG)?

Updated: Aug 27, 2018
  • Author: Abbas A Jowkar, MBBS; Chief Editor: Nicholas Lorenzo, MD, CPE, MHCM, FAAPL  more...
  • Print

Based on recent advances in understanding the various underlying antibodies that cause myasthenia gravis and differences in how they present clinically and their response to various therapies, it is suggested that patients with myasthenia gravis should be classified into subgroups. Subgroups are based on the profile of serum autantibodies, the age of onset, the presence or absence of thymic pathology, and the distribution of clinical weakness. [5]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!